Role of p53 immunohistochemistry in differentiating reactive gliosis from malignant astrocytic lesions

American Journal of Surgical Pathology

Volumn 20, Issue 9, 1996, Pages 1086-1090

  Yaziji, Hadi ^a,b,c,d   Massarani Wafai, Kazan ^a   Gujrati, Meena ^a   Kuhns, James G ^a   Martin, Alvin W ^a   Parker Jr , Joseph C ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b Norton Healthcare   (United States)

^c LOYOLA UNIVERSITY   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

Astrocytoma; Astrogliosis; Brain biopsy; p53; Progressive multifocal leukoencephalopathy; Reactive gliosis; Tumor suppresser gene

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CHILD; DIFFERENTIAL DIAGNOSIS; FEMALE; GLIOBLASTOMA; GLIOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN DISEASES; BRAIN NEOPLASMS; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029822821     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199609000-00006     Document Type: Article

References (39)

1. Ambros RA, Ross JS, Kallakury BVS, et al. p53 gene status in endometrial carcinoma showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Patlwl 1995:8:441-5.
2. Ariza A, Mate J, Fernandez-Vasalo A, et al. p53 and proliferating cell nuclear antigen expression in JC virus-infected cells of progressive multifocal leukoencephalopathy. Hum Pallwl 1994:25:1341-5.
3. Battifora H. p53 immunohistochemistry: a word of caution. Hum Patlwl !994;25:435-7.
4. Benchimol S, Lane DP. p53: Oncogene or anti-oncogene? Genes Dev 1990;4:1-8.
5. Burger PC, Scheithauer BW. Tumors of the central nervous system, 3rd ed. Washington, D.C. Armed Forces Institute of Pathology, 1994:25-161.
6. Cagle PT, Brown RW, Lebovitz, RM. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Patlwl !994;25:443-8.
7. Calamari S, Brown RW, Cagle PT. p53 immunostaining in the differentiation of inflammatory pseudotumor of the lung from sarcoma [Abstract]. Lab Invest 1994;70:I49A.
8. Dowell SP, Wilson POG, Derias NW, Lane DP, Hall PA. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Rex I994;54: 2914-8.
9. Ellison DW, Gatter KC, Steart PV, Lane DP, Weller RO. Expression of the p53 protein in a spectrum of astrocytic tumors. J Puthol 1992;l68:383-6.
10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppresser gene: clues to cancer etiology and molecular pathogenesis. Cancer Res I994;54: 4855-78.
11. Haapasalo H, Isola J, Sallinen P, Kalimo H, Heiin H, Rantala I. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. Am J Patlwl 1993; 142:1347-51.
12. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV irradiated normal human skin. Oncogene !993;8:203-7.
13. Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? revisited. J Puthol I994;172:l-4.
14. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppresser gene. N Engl J Met! 1993:329:1318-27.
15. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991:253:49-53.
16. Iggo R, Gatter K, Bartek J, Lane DP. Harris A. Increased expression of mutant forms ofp53 oncogene in primary lung cancer. Lancet 1990:335:675-9.
17. luzzolino P, Ghimenton C, Nicolato A, et al. p53 protein in low-grade astrocytomas: a study with long-term follow-up. BrJ Cancer I994;69:586-9I.
18. Kafiri G, Thomas DM, Shepherd NA, et al. p53 expression in common in malignant mesothelioma. Histopathology 1992:21:331-4.
19. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991:51:6304-11.
20. Kinzler K.W, Vogeistein B. Cancer therapy meets p53. N EnglJ Mcd 1994:331:49-50.
21. Koga H, Zhang S, Kumanishi T, et al. Analysis of p53 gene mutation in low- and high-grade astrocytomas by polymerase chain reaction-single-strand conformation polymorphism and immunohistochemistry. Acta Neiiropathol 1994; 87:225-32.
22. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild type p53 is a cell cycle checkpoint determinant following irradiation. Proc Nail AcaJ Sci !992;89:749l-5.
23. Lane DP. On the expression of the p53 protein in human cancer. Mol Bio Rep I994;l9:23-9.
24. Lane DP. p53, guardian of the genome. Nature I992;358: 15-6.
25. Lane DP, Crawford LV. T antigen is bound to a host protein in SV 40-transformed cells. Nature !979;278:26l-3.
26. Louis DN. The p53 gene and protein in human brain tumors. J Neiiropathol Exp Neurol 1994;53:l 1-21.
27. Macgeoch C, Barnes DM, Newton JA, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Mark 1993;! 1:239-50.
28. Mayall FG, Goddard H, Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. J Pallml I992;I68:377-8I.
29. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature !992;358:80-3.
30. Pezella F, Micklem K, Turley H, et al. Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin I'atlwl 1994;47:592-6.
31. Prives C, Manfred! JJ. The p53 tumor suppresser protein: meeting review. Genes Development 1993:7:529-34.
32. Rameal M, Lemmens G, Eerdekens C, et al. Immunoreactivity for p53 protein in malignant mesothelioma and nonneoplastic mesothelium. J Pulhol 1992:168:371-5.
33. Rasheed BKA, McLendon RE, Herndon JE, et" al. Alterations of the TP53 gene in human gliomas. Cancer Res 1994; 54:1324-30.
34. Sarkar FH, Kupsky WJ, Li YW, Sreepathi P. Analysis of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand conformation polymorphism and DNA sequencing. Diagn Mol Patlwl 1994:3:2-8.
35. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 1992:355:846-7.
36. Werness BA, Levine AJ, Howley PM. Association of human papilloma virus types 16 and 18 E6 protein with p53. Science 1990:248:76-9.
37. Wu JK, Zhen Y, Darras BT. Frequency of p53 tumor suppresser gene mutation in human primary brain tumors. Neurosurgery 1993:33:824-29.
38. Wynford-Thomas D. p53 in tumour pathology: can we trust immunohistochemistry? J Patlwl 1992:166:329-30.
39. Zagzag D, Miller DC, Kleinmann GM, et al. Demyelinating disease versus tumor in surgical neuropathology. Am J Surf; Patliol 1993:17:537-45.